Investors should consider Oscar Health (OSCAR) as a high-conviction growth play, given its massive 53% year-over-year revenue growth and a valuation that remains "dirt cheap" relative to its peers. The company is aggressively targeting the gig economy and employer-sponsored ICHRAs, positioning it to capture a more profitable and less regulated segment of the healthcare market. Management’s conservative Medical Loss Ratio (MLR) guidance of 83% suggests a high likelihood of future earnings beats if they maintain their current operational efficiency. OSCAR is also leveraging AI agents to structurally lower costs and improve margins, a technological edge that traditional insurers like UnitedHealth Group (UNH) may struggle to replicate quickly. With a target of $19 billion in revenue by 2026, this stock offers a significant contrarian opportunity for those looking to diversify into high-growth healthcare.

Oscar Health (OSCAR)

• Oscar Health reported a strong Q1 with 53% year-over-year revenue growth, signaling significant consumer adoption and business momentum. • The company is currently guiding for up to $19 billion in revenue by 2026, up from its current $13 billion level. • Management is maintaining a conservative Medical Loss Ratio (MLR) guidance of 83%, despite reporting a much stronger 70.5% in Q1. • The MLR represents the percentage of premiums spent on clinical services; a lower number indicates higher profitability for the insurer. • The company holds $8.1 billion in cash and investments, though much of this is "float" (premiums held to pay future claims). • Oscar is leveraging AI agents to help members find cheaper drug prices and generic alternatives, which could structurally lower their MLR and improve margins. • New growth initiatives include: • ICHRAs: Selling health plans directly to employers, which is less regulated and potentially more profitable than the Affordable Care Act (ACA) market. • Neutral Shopping Platform: A marketplace for other providers to sell products, expected to become material by 2027. • Geographic Expansion: Testing profitability in smaller states like Arizona before full rollouts.

Takeaways

• Valuation Disconnect: The stock is described as "dirt cheap" relative to its growth. Using a Market Cap / Gross Profit / Revenue Growth metric, it scores 0.049, making it one of the cheapest high-growth stocks identified by the analyst. • Conservative Guidance: There is a strong belief that management is "sandbagging" (under-promising) their numbers. If the MLR remains lower than the guided 83%, earnings could significantly outperform expectations. • Efficiency Play: Oscar is using its smaller, more agile size to use AI for reducing SG&A expenses and member spend, which traditional "TradHealth" players (like UNH) may struggle to implement as quickly. • Potential Catalysts: • Continued clarification of the balance sheet and "float" to traditional analysts. • Political discussions regarding the return or extension of ACA subsidies. • Technical bullishness as the stock has already seen a 90% recovery since late March.

Health Insurance Sector (Traditional Healthcare)

• The market currently shows a lack of interest in non-AI sectors, leaving high-growth healthcare companies like Oscar "left for dead" in terms of valuation. • Traditional players like UnitedHealth Group (UNH) are also facing market skepticism, suggesting a broader sector-wide valuation compression. • There is a shifting consumer trend toward the "gig economy" (Uber, DoorDash workers) who prefer catastrophic-oriented, high-deductible plans (Bronze plans), which Oscar is actively targeting.

Takeaways

• Contrarian Opportunity: While the health insurance industry is often disliked by investors due to complexity and regulation, the current valuation of growth-oriented players provides a high "margin of safety." • Demographic Shift: Investors should look for companies that cater to the health needs of urban populations and gig workers, as data suggests these members may be healthier and more profitable than those in rural areas.